Removing body clock gene protects mice against pneumonia
(University of Oxford) This is the first time a clock gene has been found to affect resistance to bacterial pneumonia, a fatal disease responsible for 5% of all deaths in the UK each year. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 6, 2020 Category: International Medicine & Public Health Source Type: news

Skin and mucous membrane lesions as complication of pneumonia
(University of Zurich) Painful inflammatory lesions of the skin and mucous membranes may occur in children who develop bacterial pneumonia. A research group at the University Children's Hospital Zurich has recently developed a new diagnostic blood test, which reliably diagnoses bacteria as the causative pathogen at an early stage, allowing more specific treatment and prediction about prognosis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 19, 2019 Category: Infectious Diseases Source Type: news

Up to 43% of Antibiotic Prescriptions in the U.S. Are Unnecessary or Improperly Written, Analysis Finds
The World Health Organization earlier this year called antimicrobial resistance—pathogens’ ability to evade medical interventions—one of the 10 largest threats to global health. In the U.S. alone, according to a recent Centers for Disease Control and Prevention (CDC) report, 35,000 people die each year due to antibiotic-resistant infections. A new study published in the BMJ points to one major propagator of the problem: doctors are prescribing antibiotics when they shouldn’t. In fact, up to 43% of U.S. antibiotic prescriptions may be “inappropriate,” according to the research. Antibioti...
Source: TIME: Health - December 12, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Research Source Type: news

FDA Approves New Indication for Delafloxacin for CABP FDA Approves New Indication for Delafloxacin for CABP
Following approval in 2017 for bacteria skin infections, the fluoroquinolone antibiotic is now indicated for adults with community-acquired bacterial pneumonia.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 25, 2019 Category: Drugs & Pharmacology Tags: Infectious Diseases News Alert Source Type: news

FDA Approves Baxdela (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
MORRISTOWN, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 25, 2019 Category: Drugs & Pharmacology Source Type: news

New Antibiotic Approved for Community-Acquired Bacterial Pneumonia
Title: New Antibiotic Approved for Community-Acquired Bacterial PneumoniaCategory: Health NewsCreated: 8/19/2019 12:00:00 AMLast Editorial Review: 8/20/2019 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - August 20, 2019 Category: Respiratory Medicine Source Type: news

FDA approves King of Prussia company's pneumonia drug
The Food and Drug Administration approved Nabriva Therapeutics' drug application for its antibiotic Xenleta. Xenleta treats community-acquired bacterial pneumonia (CABP), a leading cause of infection-related deaths in the United States. Nabriva's stock was up 20% at $2.67 per share in after-hours trading Monday. According to the company, about 5 million cases of pneumonia are reported in the United Sta tes each year, and pneumonia is the fifth-leading cause of hospitalizations. Nabriva said Xenleta… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2019 Category: Biotechnology Authors: John George Source Type: news

FDA OKs First-in-Class Antibiotic Lefamulin (Xenleta) for CABP FDA OKs First-in-Class Antibiotic Lefamulin (Xenleta) for CABP
The new semisynthetic pleuromutilin antibiotic will be available for oral and IV administration with a short 5- to 7-day course of therapy for community-acquired bacterial pneumonia (CABP).FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 20, 2019 Category: Consumer Health News Tags: Infectious Diseases News Alert Source Type: news

FDA Approves Xenleta (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)
DUBLIN, Ireland, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 20, 2019 Category: Drugs & Pharmacology Source Type: news

FDA approves new antibiotic to treat community-acquired bacterial pneumonia
The FDA approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 19, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

New Antibiotic Xenleta Approved for Community-Acquired Bacterial Pneumonia
MONDAY, Aug. 19, 2019 -- Xenleta (lefamulin) has been approved to treat adults with community-acquired bacterial pneumonia, the U.S. Food and Drug Administration announced today. Dosing of Xenleta is either an oral administration of 600 mg every 12... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 19, 2019 Category: General Medicine Source Type: news

Practical Tips for Diagnosing and Treating Bacterial Pneumonia in the Nursing Home
A clinical diagnosis of bacterial pneumonia in nursing home residents most often can be treated with a single oral course of antibiotic therapy targeted toward community-acquired pneumonia pathogens, Ghinwa Dumyati, MD, said at the AMDA — The Society for Post-Acute and Long-Term Care Medicine’s annual conference. (Source: Caring for the Ages)
Source: Caring for the Ages - July 30, 2019 Category: Health Management Authors: Christine Kilgore Source Type: news

Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia
TUESDAY, June 11, 2019 -- Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 11, 2019 Category: General Medicine Source Type: news

FDA expands Merck antibiotic indication to pneumonia treatment
The previously FDA-approved drug, Zerbaxa, is now indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 4, 2019 Category: Pharmaceuticals Source Type: news

Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia
TUESDAY, June 4, 2019 -- Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older, the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2019 Category: Pharmaceuticals Source Type: news

FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia
FDA today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 4, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Dual Antibiotic Zerbaxa Gets FDA Nod for Bacterial Pneumonia Dual Antibiotic Zerbaxa Gets FDA Nod for Bacterial Pneumonia
Zerbaxa (ceftolozane and tazobactam) for hospital- and ventilator-associated bacterial pneumonia was initially approved for complicated intra-abdominal and urinary tract infections.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 4, 2019 Category: Drugs & Pharmacology Tags: Pulmonary Medicine News Alert Source Type: news

FDA Approves Zerbaxa (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Monday, June 3, 2019 -- KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Merck’s supplemental New Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 3, 2019 Category: Drugs & Pharmacology Source Type: news

Merck wins U.S. FDA approval for expanded use of antibiotic
The U.S. Food and Drug Administration said https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia on Monday it approved expanded use of Merck& Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Characteristics and Outcomes of Patients With and Without Type 2 Diabetes Mellitus and Pulmonary Sepsis
To date, studies have provided conflicting results regarding the impact of type 2 diabetes mellitus (DM) on sepsis-related outcomes. Our objective is to understand the impact of type 2 DM in bacterial pneumonia and sepsis-related intensive care unit (ICU) outcomes. Our findings demonstrated that type 2 DM does not increase the overall mortality. Our findings of increased mortality in both type 2 DM patients with lower admission glucose, and non-DM patients with higher mean glucose during the hospital stay needs to be further evaluated. Future studies in regards to this could lead to personalized glucose treatment goals for...
Source: Current Awareness Service for Health (CASH) - April 25, 2019 Category: Consumer Health News Source Type: news

Omadacycline Found Similar to Usual Care for CABP, ABSSSI (CME/CE)
(MedPage Today) -- Well-tolerated option for select patients with community-acquired bacterial pneumonia and skin infections (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 13, 2019 Category: Infectious Diseases Source Type: news

Omadacycline Noninferior to Moxifloxacin for Pneumonia
WEDNESDAY, Feb. 6, 2019 -- Omadacycline is noninferior to moxifloxacin for community-acquired bacterial pneumonia and noninferior to linezolid for acute bacterial skin infections, according to two studies published in the Feb. 7 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2019 Category: Pharmaceuticals Source Type: news

Second Child In Mass. Dies From Flu-Related Illness
BOSTON (CBS) — A four-year-old girl from Framingham has died from a flu-related illness, the second flu-related death of a child in Massachusetts this week, the Framingham Public Health Department announced Friday. According to the DPH, the cases are unrelated “and were confirmed by the DPH’s State Public Health Laboratory.” The death of a 12-year-old boy from Milford with a flu-related illness was announced Thursday. The boy’s mother told WBZ-TV he got his flu shot this year, but still got sick. He stayed home from school for multiple days until he developed a bacterial in...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 1, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Seen On WBZ-TV Syndicated Local Flu Flu Deaths Local TV Source Type: news

What Are Common Causes of Blindness in Children?
Discussion According to the World Health Organization, about 1.3 billion people have some form of visual impairment. Most people with visual impairments are>50 years old, more are female than male, and more live in resource-limited areas than resource-rich areas. Most visual impairments are avoidable (80%) in all age groups with the leading causes globally and across ages being uncorrected refractive errors and cataracts. The most common causes of blindness are: Refractive errors, uncorrected Cataract Age-related macular degeneration Glaucoma Diabetic retinopathy Corneal opacity Trachoma The exact numbers vary by regi...
Source: PediatricEducation.org - January 28, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

A traditional Chinese medicine proves effective in treating bacterial pneumonia
(Natural News) A herbal compound used in traditional Chinese medicine can be used to treat a type of pneumonia caused by multidrug-resistant bacteria, according to researchers from the Henan University of Chinese Medicine. In their study, which was published in BMC Complementary and Alternative Medicine, they suggested that Dusuqing granules have the ability to inhibit the effects of Klebsiella... (Source: NaturalNews.com)
Source: NaturalNews.com - January 21, 2019 Category: Consumer Health News Source Type: news

Antibiotic developer Nabriva enters into $75M loan deal
With two potential product launches on the horizon, Nabriva Therapeutics has entered into loan agreement valued at up to $75 million with Hercules Capital. Earlier this week, Nabriva (NASDAQ: NBRV) filed two new drug applications seeking approval for intravenous and oral formulations of Lefamulin to treat community-acquired bacterial pneumonia. Last month the company — which is based in Dublin, Ireland, and has its U.S. headquarters in King of Pru ssia — filed a new drug application for Contepo,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 21, 2018 Category: American Health Authors: John George Source Type: news

Nabriva files 2 NDAs seeking approval for experimental pneumonia treatment
Nabriva Therapeutics on Thursday submitted two new drug applications with the Food and Drug Administration seeking marketing approval for intravenous and oral formulation of Lefamulin to treat community-acquired bacterial pneumonia in adults. “The submission of the Lefamulin NDAs marks another major milestone for Nabriva, demonstrating our commitment to develop novel anti-infective agents that address the urgent, unmet medical need faced by patients with serious infections,” said Dr. Jennifer… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 20, 2018 Category: Health Management Authors: John George Source Type: news

Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
DUBLIN, Ireland, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 20, 2018 Category: Drugs & Pharmacology Source Type: news

With these nanoparticles, a simple urine test could diagnose bacterial pneumonia
(Massachusetts Institute of Technology) MIT researchers have now developed a nanoparticle-based technology that could be used distinguish between bacterial and viral forms of pneumonia. The technology could also be used to monitor whether antibiotic therapy has successfully treated the infection. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 29, 2018 Category: Infectious Diseases Source Type: news

FDA Approves Nuzyra (omadacycline) for Community-Acquired Bacterial Pneumonia and Acute Skin and Skin Structure Infections
BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced that the U.S. Food and Drug Administration (FDA) has approved Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 3, 2018 Category: Drugs & Pharmacology Source Type: news

Novel nanoparticle-based approach detects and treats oral plaque without drugs
(University of Illinois College of Engineering) When the good and bad bacteria in our mouth become imbalanced, the bad bacteria form a biofilm (aka plaque), which can cause cavities, and if left untreated over time, can lead to cardiovascular and other inflammatory diseases like diabetes and bacterial pneumonia. A team of researchers from the University of Illinois has recently devised a practical nanotechnology-based method for detecting and treating the harmful bacteria that cause plaque and lead to tooth decay and other detrimental conditions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 17, 2018 Category: International Medicine & Public Health Source Type: news

Omadacycline Recommended by FDA Panel for ABSSSI and CABP Omadacycline Recommended by FDA Panel for ABSSSI and CABP
An FDA panel recommended omadacycline for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 11, 2018 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

U.S. FDA panel backs approval of Paratek's antibiotic
A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections. (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Paratek Antibiotic Noninferior to Current Treatments-FDA Staff Paratek Antibiotic Noninferior to Current Treatments-FDA Staff
Paratek Pharmaceuticals Inc's new antibiotic for bacterial pneumonia and skin infections is not inferior to current treatments, U.S. Food and Drug Administration staff reviewers said on Monday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Advisors Set to Consider Next-Gen Tetracycline for CABP
(MedPage Today) -- Omadacycline promising in community-acquired bacterial pneumonia and more (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 7, 2018 Category: Primary Care Source Type: news

King of Prussia biopharm firm posts positive study data for experimental pneumonia therapy
Nabriva Therapeutics announced positive results Monday from its second large-scale, late-stage clinical trial of its experimental therapy for community-acquired bacterial pneumonia (CABP). The biopharmaceutical company, which has operations in Dublin, Ireland and King of Prussia, plans to file a new drug application for the therapy – called Lefamulin – with the Food and Drug Administration during the fourth quarter of this year. Nabriva’s stock surged by more than 20 percent in pre-market… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 21, 2018 Category: Biotechnology Authors: John George Source Type: news

What Causes Hyponatremia?
Discussion Normal kidneys regulate water balance to maintain a plasma osmolality of 275-290 mOsm/kg normally. Thirst and arginine vasopressin or antidiuretic hormone (ADH) are the primary regulators of plasma osmolality. ADH is made in the hypothalamus and released by the posterior pituitary gland. ADH acts on the kidney’s distal collecting duct to increase water reabsorption. ADH is appropriately released in hypovolemic states, such as dehydration caused by gastroenteritis. ADH has an ~10 minute half-life and therefore can respond to rapid changes in volume status. Sodium balance is regulated by aldosterone (as part...
Source: PediatricEducation.org - April 23, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Boosting natural defenses to fight antibiotic-resistant pneumonia
(Boston Children's Hospital) Antibiotic resistance is a growing threat in bacterial pneumonia. While immune-stimulating treatments can help the body fight the invaders, they can also cause inflammation that damages and weakens lung tissue. But new research suggests a way to enhance bacterial killing without the inflammation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 4, 2018 Category: International Medicine & Public Health Source Type: news

Utah mom loses hands and legs after rare complications from a cold
Tiffany King, 38, caught a cold in Springsville, Utah, in January that led to viral and bacterial pneumonia and sepsis. When she woke from a coma she learned four of her limbs needed to be amputated. (Source: the Mail online | Health)
Source: the Mail online | Health - March 20, 2018 Category: Consumer Health News Source Type: news

Blood stored longer may be less safe for patients with massive blood loss and shock
(University of Alabama at Birmingham) In a collaborative study using a mouse model, researchers have found mechanistic links between older stored red blood cell transfusions and subsequent bacterial pneumonia. This may reveal new approaches to improve safety of stored red blood cell transfusions. The key player is free heme, a breakdown product from degraded red blood cells (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2018 Category: International Medicine & Public Health Source Type: news

Nerve cells found to suppress immune response during deadly lung infections
(Harvard Medical School) Neurons that carry nerve signals to and from the lungs suppress immune response during fatal lung infections with the bacterium Staphylococcus aureus.Animal experiments show that disabling these neurons can boost immune response and promote bacterial clearance to aid recovery.Targeting neuro-immune signaling in the lungs can pave the way to nonantibiotic therapies for bacterial pneumonia. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 5, 2018 Category: Infectious Diseases Source Type: news

FDA Approves AVYCAZ(R) (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
First Gram-Negative Antibiotic Approved in the U.S. to Treat HABP/VABP in Over 15 Years DUBLIN, Feb. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. F... Biopharmaceuticals, FDA Allergan, AVYCAZ, ceftazidime, avibactam, Bacterial Pneumonia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 2, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Avycaz (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
DUBLIN, Feb. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Allergan's supplemental New Drug Application (sNDA) to expand the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 1, 2018 Category: Drugs & Pharmacology Source Type: news

Pneumonia: Treatment with vaccines instead of antibiotics
(University of Zurich) A properly functioning immune system is key to resolve bacterial pneumonia. Researchers from the University Children's Hospital Zurich and UZH working with an international team have now found that specific immune cells are crucial for recovery. The researchers' work paves the way for developing new vaccines, which would also counteract the emerging resistance to antibiotics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 21, 2017 Category: International Medicine & Public Health Source Type: news

More Laboratory Tests Performed at Major Teaching Hospitals
More tests per day for bacterial pneumonia, cellulitis at major teaching versus nonteaching hospitals (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 14, 2017 Category: Respiratory Medicine Tags: Family Medicine, Geriatrics, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pathology, Pulmonology, Journal, Source Type: news

Paratek reports positive data from Phase III trial of omadacycline
Paratek Pharmaceuticals has reported positive safety and efficacy data from a Phase III clinical trial (OPTIC) of its investigational antibiotic, omadacycline, for community-acquired bacterial pneumonia (CABP). (Source: Drug Development Technology)
Source: Drug Development Technology - October 9, 2017 Category: Pharmaceuticals Source Type: news

US FDA grants priority review status to Allergan ’s sNDA for Avycaz
The US Food and Drug Administration (FDA) has granted priority review status for Allergan ’s supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam) to treat hospital-acquired bacterial pneumonia / ventilator-associated bacteri… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 3, 2017 Category: Pharmaceuticals Source Type: news

Nabriva's Pneumonia Drug Succeeds in Late-stage Trial Nabriva's Pneumonia Drug Succeeds in Late-stage Trial
Nabriva Therapeutics Plc has reported that its experimental antibiotic for community-acquired bacterial pneumonia (CABP) met the main goal of a late-stage study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Nabriva's pneumonia drug succeeds in late-stage trial, shares soar
(Reuters) - Nabriva Therapeutics Plc shares more than doubled in premarket trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia met the main goal of a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Nabriva's pneumonia drug meets main goal in late-stage study
(Reuters) - Nabriva Therapeutics Plc said on Monday its experimental treatment for community-acquired bacterial pneumonia met the main goal in a late-stage study, sending its shares up more than 70 percent in premarket trading. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news